SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Returns to R&D on new drug introductions in the 1980s
5 references·16 citing·45 second hop
Returns to R&D on new drug introductions in the 1980s (1994)Returns to R&D on new drug introductions …On the Misuse of Accounting Rates of Return to Infer Monopoly Profits (2016)On the Misuse of Accounting R…Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)Brand Loyalty, Entry, and Pri…Cost of innovation in the pharmaceutical industry (1991)Cost of innovation in the pha…A New Look at the Returns and Risks to Pharmaceutical R&D (1990)A New Look at the Returns and…Industrial Research and Development, Intangible Capital Stocks, and Firm Profit Rates (1978)Industrial Research and Devel…The Cost of Drug Development (2015)The Cost of Drug DevelopmentThe Pharmaceutical Industry (2013)The Pharmaceutical IndustryInnovation and Marketing in the Pharmaceutical Industry (2013)Innovation and Marketing in t…Follow-on biologics: data exclusivity and the balance between innovation and competition (2008)Follow-on biologics: data exc…Generic competition and market exclusivity periods in pharmaceuticals (2007)Generic competition and marke…Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry (2005)Drug Prices and Research and …Cutting the cost of drug development? (2004)Cutting the cost of drug deve…An R&D Race with Knowledge Accumulation (2003)An R&D Race with Knowledge Ac…Uncertainty and the size distribution of rewards from innovation (2001)Uncertainty and the size dist…The determinants of pharmaceutical research and development expenditures (2001)The determinants of pharmaceu…Uncertainty and the size distribution of rewards from innovation (2000)Uncertainty and the size dist…New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms (2000)New Drug Innovation and Pharm…Effective patent life in pharmaceuticals (2000)Effective patent life in phar…Chapter 25 The pharmaceutical industry (2000)Chapter 25 The pharmaceutical…Market Structure, R&D and Advertising in the Pharmaceutical Industry (1999)Market Structure, R&D and Adv…Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions (1997)Pharmacy benefit management, …Industrial Market Structure and Economic Performance. (1971)Business Cycles and the Relationship between Concentration and Price-Cost Margins (1986)Strategic Group Formation and Performance: The Case of the U.S. Pharmaceutical Industry, 1963–1982 (1987)A New Way to Measure Competition (2008)Industrial research and technological innovation (1968)Social and Private Rates of Return from Industrial Innovations* (1977)R & D, Market Structure and Profits: A Value-Based Approach (1984)DIVERSIFYING ENTRY: SOME EX ANTE EXPLANATIONS FOR POSTENTRY SURVIVAL AND GROWTH. (1996)Theorie der wirtschaftlichen Entwicklung (2003)The effects of R&D and advertising on firm value: an examination of manufacturing and nonmanufacturing firms (2005)Product differentiation advantages of pioneering brands (1980)Generic Entry and the Pricing of Pharmaceuticals (1997)Uncertainty and Learning in Pharmaceutical Demand (2005)Killer Acquisitions (2020)Dynamic Noncooperative Game Theory (1982)Innovation and Learning: The Two Faces of R & D (1989)Measuring Competence? Exploring Firm Effects in Pharmaceutical Research (1994)Chapter 30 A Framework for Applied Dynamic Analysis in IO (2007)Why Put All Your Eggs in One Basket? A Competition-Based View of How Technological Uncertainty Affects a Firm’s Technological Specialization (2012)Platform Synergy: Architectural Origins and Competitive Consequences (2018)Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs (2000)The price of innovation: new estimates of drug development costs (2003)Making a difference: 30 years of TDR (2008)The Cost-Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies (2011)The risks of risk aversion in drug regulation (2013)Generic Drug Industry Dynamics (2005)Balancing Innovation and Access: Patent Challenges Tip the Scales (2009)When Do Generics Challenge Drug Patents? (2011)Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry (2016)Capital-Market Imperfections and Investment (1997)Does Public Scientific Research Complement Private Investment in Research and Development in the Pharmaceutical Industry? (2007)Asymmetric Growth and Institutions in an Interdependent World (2017)Public sector financial support for late stage discovery of new drugs in the United States: cohort study (2019)Conditional logit analysis of qualitative choice behavior (1972)Qualitative Response Models: A Survey (1994)Sources and Financial Consequences of Radical Innovation: Insights from Pharmaceuticals (2003)The cost of biopharmaceutical R&D: is biotech different? (2007)Essential medicines for universal health coverage (2016)Appropriating the Returns from Industrial Research and Development (1987)Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery (1996)Managed Care or Managed Inequality? A Call for Critiques of Market‐Based Medicine (2002)Post-TRIPS Options for Access to Patented Medicines in Developing Nations (2002)Pharmaceutical pricing policies in a global market (2008)Innovative productivity and returns to scale in the pharmaceutical industry (1993)Pricing, Profits, and Technological Progress in the Pharmaceutical Industry (1993)
this work references cited by second hop

References

  • 2016On the Misuse of Accounting Rates of Return to Infer Monopoly Profits772 cited
  • 1991Cost of innovation in the pharmaceutical industry763 cited
  • 1992Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act574 cited
  • 1990A New Look at the Returns and Risks to Pharmaceutical R&D286 cited
  • 1978Industrial Research and Development, Intangible Capital Stocks, and Firm Profit Rates227 cited

Cited by

  • 2013The Pharmaceutical Industry196 cited
  • 2004Cutting the cost of drug development?187 cited
  • 2007Generic competition and market exclusivity periods in pharmaceuticals169 cited
  • 2003An R&D Race with Knowledge Accumulation168 cited
  • 2005Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry149 cited
  • 2000Uncertainty and the size distribution of rewards from innovation143 cited
  • 2015The Cost of Drug Development121 cited
  • 2001Uncertainty and the size distribution of rewards from innovation116 cited
  • 1999Market Structure, R&D and Advertising in the Pharmaceutical Industry106 cited
  • 2001The determinants of pharmaceutical research and development expenditures

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

97 cited
  • 1997Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions94 cited
  • 2000Effective patent life in pharmaceuticals91 cited
  • 2008Follow-on biologics: data exclusivity and the balance between innovation and competition89 cited
  • 2000New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms78 cited
  • 2013Innovation and Marketing in the Pharmaceutical Industry77 cited
  • 2000Chapter 25 The pharmaceutical industry76 cited